Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsHideho Okada, Walter J. Storkus, Junichi Eguchi, Hidemitsu Sato
Life of this patent
Estimating the term…
Abstract
The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.
Claims10
An isolated peptide comprising ALPFGFILV (SEQ ID NO:3).
A composition comprising a peptide comprising ALPFGFILV (SEQ ID NO:3) and a physiologically-acceptable earner.
Dependencies are inferred from the claim text.